Development and validation of UV/VIS spectroscopy method for determination of atezolizumab in pharmaceutical products

Aim: The aim of this study was to develop and validate a simple, fast, and reliable UV visible methodology for the determination of atezolizumab in pharmaceutical products. Methods: The maximum wavelength of atezolizumab was determined using a UV/Vis spectrum and the calibration curve has been established. Validation studies were carried out to determine the reliability of the spectrophotometer method used in quantification of pharmaceutical products. Results: According to the experimental data, the developed method was linear in a range varying from 0.10 to 1.50 mg.mL-1 determined by 6 individuals calibrations points. The r2 value was 0.9995 indicating a 99.95% correlation in linearity and precision. The robustness showed good and similar values and the limit of detection and limit of quantification were 0.005 mg.mL-1 and 0.018 mg.mL-1, respectively. Conclusion: The data corroborates the reliability as applicability of the developed UV/Vis spectroscopy method for quantitatively determining the amount of atezolizumab in pharmaceutical products.